Duality Biotherapeutics Inc.

Duality Biotherapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of next-generation antibody-drug conjugate (ADC) therapeutics. Headquartered in Shanghai, China, Duality Biotherapeutics focuses on creating innovative targeted treatments for cancer and autoimmune diseases. Its pipeline features several advanced ADC candidates, such as DB-1303, a HER2-targeted therapy for cancers including endometrial and breast cancer, and DB-1311, which targets B7-H3 and is in development for a range of difficult-to-treat solid tumors, including small-cell lung cancer and prostate cancer. The company has established strategic collaborations with global pharmaceutical leaders to advance and commercialize its therapies, aiming to complement or offer alternatives to traditional chemotherapy. Duality Biotherapeutics plays a significant role in the growing biotechnology sector, leveraging cutting-edge research to address unmet clinical needs in oncology. With a solid presence in both domestic and international markets, the firm stands out for its commitment to advancing precision medicine through novel ADC platforms.